Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human B7-H2 Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 2 publications
Supplier: R&D Systems MAB165500
This item is not returnable.
View return policy
Description
B7-H2/ICOSLG Monoclonal specifically detects B7-H2/ICOSLG in Human samples. It is validated for Flow Cytometry, Neutralization, CyTOF-ready.Specifications
B7-H2/ICOSLG | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
B7H2, B7H2B7 homolog 2, B7-H2B7-related protein 1, B7RP-1, B7RP1B7-like protein Gl50, B7RP-1LICOS, CD275, CD275 antigen, GL50, GL50transmembrane protein B7-H2 ICOS ligand, ICOSL, ICOS-L, ICOSLG, inducible T-cell co-stimulator ligand, KIAA0653ICOS ligand | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
23308 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG2b |
Flow Cytometry, Neutralization, CyTOF | |
136726 | |
Flow Cytometry 2.5 ug/10^6 cells, Neutralization 1-4 ug/mL, CyTOF-ready | |
O75144 | |
ICOSLG | |
Mouse myeloma cell line NS0-derived recombinant human B7-H2 Asp19-Ser258 Accession # O75144 | |
500 μg | |
Primary | |
Detects human B7-H2 in direct ELISAs. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) B7-1, rhB7-2, rhB7-H1, rhB7-H3, or recombinant mouse B7-H2 is observed. | |
Human | |
Supernatant |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction